MX2021013356A - Tratamiento y prevencion de enfermedades metabolicas. - Google Patents
Tratamiento y prevencion de enfermedades metabolicas.Info
- Publication number
- MX2021013356A MX2021013356A MX2021013356A MX2021013356A MX2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A MX 2021013356 A MX2021013356 A MX 2021013356A
- Authority
- MX
- Mexico
- Prior art keywords
- metabolic diseases
- prevention
- treatment
- methods
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906291.8A GB201906291D0 (en) | 2019-05-03 | 2019-05-03 | Treatment and prevention of metabolic diseases |
| GBGB1906597.8A GB201906597D0 (en) | 2019-05-03 | 2019-05-10 | Treatment and prevention of metabolic diseases |
| GBGB2001013.8A GB202001013D0 (en) | 2020-01-24 | 2020-01-24 | Treatment and prevention of metabolic diseases |
| GBGB2001896.6A GB202001896D0 (en) | 2020-02-12 | 2020-02-12 | Treatment and prevention of metabolic diseases |
| GBGB2002030.1A GB202002030D0 (en) | 2020-02-14 | 2020-02-14 | Treatment and prevention of metabolic diseases |
| PCT/EP2020/062193 WO2020225147A1 (en) | 2019-05-03 | 2020-05-01 | Treatment and prevention of metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013356A true MX2021013356A (es) | 2022-03-11 |
Family
ID=73051262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013356A MX2021013356A (es) | 2019-05-03 | 2020-05-01 | Tratamiento y prevencion de enfermedades metabolicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11813311B2 (enExample) |
| EP (1) | EP3962936A1 (enExample) |
| JP (1) | JP7595028B2 (enExample) |
| KR (1) | KR20220050087A (enExample) |
| CN (1) | CN114364693A (enExample) |
| AU (1) | AU2020268619B2 (enExample) |
| BR (1) | BR112021021921A2 (enExample) |
| CA (1) | CA3146344A1 (enExample) |
| CL (1) | CL2021002878A1 (enExample) |
| MX (1) | MX2021013356A (enExample) |
| PH (1) | PH12021552763A1 (enExample) |
| TW (1) | TW202108606A (enExample) |
| WO (1) | WO2020225147A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021021921A2 (pt) * | 2019-05-03 | 2021-12-28 | Nat Univ Singapore | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica |
| CA3169779A1 (en) | 2020-02-28 | 2021-09-02 | Andrew Mark Griffin | Kcnt1 inhibitors and methods of use |
| US12400326B2 (en) * | 2020-06-09 | 2025-08-26 | Temasek Life Sicences Laboratory Limited | Automated disease detection system |
| CN113041248A (zh) * | 2021-04-26 | 2021-06-29 | 北京亿药科技有限公司 | Ravoxertinib在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用 |
| WO2023006765A1 (en) * | 2021-07-26 | 2023-02-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of alcoholic liver disease |
| MX2024002611A (es) * | 2021-08-30 | 2024-05-29 | Lassen Therapeutics 1 Inc | Anticuerpos anti-il-11ra. |
| CN114081882B (zh) * | 2021-11-15 | 2023-01-10 | 中国科学院深圳先进技术研究院 | 一种a-fabp蛋白抑制剂及其应用 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| EP4702047A1 (en) | 2023-04-25 | 2026-03-04 | VVB Bio Pte. Ltd. | Anti il-11 antibody |
| WO2024259282A2 (en) * | 2023-06-15 | 2024-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Interleukin 11 polypeptides and methods of use |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| EP1311277A4 (en) | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | METHODS OF FIBROSIS MODULATION |
| WO2003049693A2 (en) * | 2001-12-06 | 2003-06-19 | Wyeth | Method and composition for inducing weight loss |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| JP5330398B2 (ja) | 2007-10-26 | 2013-10-30 | シーエスエル、リミテッド | サイトカインムテイン |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| CN117843785A (zh) * | 2013-02-07 | 2024-04-09 | Csl有限公司 | Il-11r结合蛋白及其应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20160038589A1 (en) | 2014-08-11 | 2016-02-11 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| WO2017141032A1 (en) | 2016-02-15 | 2017-08-24 | Oxford University Innovation Limited | Treatment of fibrotic disorders |
| GB201621431D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore The | Decoy cytokine receptor |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US20180186871A1 (en) * | 2016-12-16 | 2018-07-05 | Singapore Health Services Pte Ltd. | Il-11 antibodies |
| GB201806918D0 (en) | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| BR112021021921A2 (pt) * | 2019-05-03 | 2021-12-28 | Nat Univ Singapore | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica |
-
2020
- 2020-05-01 BR BR112021021921A patent/BR112021021921A2/pt unknown
- 2020-05-01 MX MX2021013356A patent/MX2021013356A/es unknown
- 2020-05-01 US US16/865,259 patent/US11813311B2/en active Active
- 2020-05-01 EP EP20721644.1A patent/EP3962936A1/en active Pending
- 2020-05-01 CA CA3146344A patent/CA3146344A1/en active Pending
- 2020-05-01 AU AU2020268619A patent/AU2020268619B2/en active Active
- 2020-05-01 WO PCT/EP2020/062193 patent/WO2020225147A1/en not_active Ceased
- 2020-05-01 JP JP2021564913A patent/JP7595028B2/ja active Active
- 2020-05-01 CN CN202080049108.3A patent/CN114364693A/zh active Pending
- 2020-05-01 PH PH1/2021/552763A patent/PH12021552763A1/en unknown
- 2020-05-01 KR KR1020217039250A patent/KR20220050087A/ko active Pending
- 2020-05-01 TW TW109114711A patent/TW202108606A/zh unknown
-
2021
- 2021-11-02 CL CL2021002878A patent/CL2021002878A1/es unknown
-
2023
- 2023-10-06 US US18/482,399 patent/US20240156913A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220050087A (ko) | 2022-04-22 |
| BR112021021921A2 (pt) | 2021-12-28 |
| JP7595028B2 (ja) | 2024-12-06 |
| TW202108606A (zh) | 2021-03-01 |
| JP2022531591A (ja) | 2022-07-07 |
| US20240156913A1 (en) | 2024-05-16 |
| AU2020268619B2 (en) | 2026-03-05 |
| CA3146344A1 (en) | 2020-11-12 |
| US20200384083A1 (en) | 2020-12-10 |
| US20210177940A2 (en) | 2021-06-17 |
| US11813311B2 (en) | 2023-11-14 |
| CL2021002878A1 (es) | 2022-10-07 |
| AU2020268619A1 (en) | 2021-12-16 |
| EP3962936A1 (en) | 2022-03-09 |
| WO2020225147A1 (en) | 2020-11-12 |
| CN114364693A (zh) | 2022-04-15 |
| PH12021552763A1 (en) | 2022-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013356A (es) | Tratamiento y prevencion de enfermedades metabolicas. | |
| CL2021002212A1 (es) | Tratamiento de lesión renal | |
| CL2020002018A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
| CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| MX379543B (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| MX390535B (es) | Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer. | |
| PH12017500583A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| PH12016501457B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2021000142A (es) | Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| CR20210499A (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| PH12021552133A1 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| EA202191115A1 (ru) | Новые пиридазины | |
| MX2020006533A (es) | Inhibidores del receptor activado por proteasa-2. |